{
    "id": 29146,
    "fullName": "CTLA4 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CTLA4 over exp indicates an over expression of the Ctla4 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1493,
        "geneSymbol": "CTLA4",
        "terms": [
            "CTLA4",
            "ALPS5",
            "CD",
            "CD152",
            "CELIAC3",
            "CTLA-4",
            "GRD4",
            "GSE",
            "IDDM12"
        ]
    },
    "variant": "over exp",
    "createDate": "01/01/2019",
    "updateDate": "01/01/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20608,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, treatment with Toripalimab (JS001) resulted in a significantly greater objective response rate (50% vs 10.7%, p=0.019) and an improved median progression-free survival (3.8 mo vs 2.2 mo) and median overall survival (9.1 mo vs 7.2 mo) in patients with neuroendocrine tumors with high expression of CTLA4 (PD-L1 greater than or equal to 10%, n=10/38) compared to patients with low expression of CTLA4 (PD-L1 less than 10%, n=28/38) (PMID: 32086343; NCT03167853).",
            "molecularProfile": {
                "id": 31081,
                "profileName": "CTLA4 over exp"
            },
            "therapy": {
                "id": 5891,
                "therapyName": "Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17958,
                    "pubMedId": 32086343,
                    "title": "Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32086343"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31081,
            "profileName": "CTLA4 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}